The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zingg, Daniel ^a   Debbache, Julien ^a   Schaefer, Simon M ^a   Tuncer, Eylul ^a   Frommel, Sandra C ^a   Cheng, Phil ^b   Arenas Ramirez, Natalia ^b   Haeusel, Jessica ^a   Zhang, Yudong ^a   Bonalli, Mario ^a   McCabe, Michael T ^c   Creasy, Caretha L ^c   Levesque, Mitchell P ^b   Boyman, Onur ^b   Santoro, Raffaella ^a   Shakhova, Olga ^a,b   Dummer, Reinhard ^b   Sommer, Lukas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR EZH2; ADENOSYLMETHIONINE DECARBOXYLASE; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; POLYCOMB REPRESSIVE COMPLEX 2;

CANCER; DISEASE TREATMENT; GENE; INHIBITION; SKIN DISORDER; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; EPIGENETIC REPRESSION; EPIGENETICS; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; INHIBITION KINETICS; MELANOMA CELL; METASTASIS; MOUSE; MOUSE MODEL; NONHUMAN; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL MELANOMA; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE; HOMEOSTASIS; KNOCKOUT MOUSE; MELANOCYTE; MELANOMA; METABOLISM; PHYSIOLOGY; SKIN TUMOR; TREATMENT OUTCOME; TUMOR INVASION;

ADENOSYLMETHIONINE DECARBOXYLASE; ANIMALS; CELL PROLIFERATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOTYPE; HOMEOSTASIS; HUMANS; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYCOMB REPRESSIVE COMPLEX 2; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84928572472     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7051     Document Type: Article

References (69)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. Braeuer, R. R. et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 27, 19-36 (2014).
3. Lito, P., Rosen, N. & Solit, D. B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409 (2013).
4. Sanchez-Laorden, B. et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci. Signal. 7, 1-12 (2014).
5. Shakhova, O. Neural crest stem cells in melanoma development. Curr. Opin. Oncol. 26, 215-221 (2014).
6. Theveneau, E. & Mayor, R. Neural crest delamination and migration: from epithelium-to-mesenchyme transition to collective cell migration. Dev. Biol. 366, 34-54 (2012).
7. Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
8. Dupin, E. & Sommer, L. Neural crest progenitors and stem cells: from early development to adulthood. Dev. Biol. 366, 83-95 (2012).
9. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
10. Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
11. Fuchs, S. et al. Stage-specific control of neural crest stem cell proliferation by the small rho GTPases Cdc42 and Rac1. Cell Stem Cell 4, 236-247 (2009).
12. Paratore, C., Goerich, D. E., Suter, U., Wegner, M. & Sommer, L. Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. Development 128, 3949-3961 (2001).
13. Kim, J., Lo, L., Dormand, E. & Anderson, D. J. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuron 38, 17-31 (2003).
14. Shakhova, O. et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat. Cell Biol. 14, 882-890 (2012).
15. Reik, W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447, 425-432 (2007).
16. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
17. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
18. Ciferri, C. et al. Molecular architecture of human polycomb repressive complex 2. Elife 1, e00005 (2012).
19. Hirabayashi, Y. et al. Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. Neuron 63, 600-613 (2009).
20. Kamminga, L. M. et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107, 2170-2179 (2006).
21. Schwarz, D. et al. Ezh2 is required for neural crest-derived cartilage and bone formation. Development 141, 867-877 (2014).
22. Sauvageau, M. & Sauvageau, G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313 (2010).
23. Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268-273 (2006).
24. McHugh, J. B., Fullen, D. R., Ma, L., Kleer, C. G. & Su, L. D. Expression of polycomb group protein EZH2 in nevi and melanoma. J. Cutan. Pathol. 34, 597-600 (2007).
25. Li, X. et al. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am. J. Pathol. 175, 1246-1254 (2009).
26. Gonzalez, M. E. et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl Acad. Sci. USA 111, 3098-3103 (2014).
27. Beguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
28. Fan, T. et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol. Cancer Res. 9, 418-429 (2011).
29. Luo, C. et al. MiR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J. Invest. Dermatol. 133, 768-775 (2012).
30. Luo, C. et al. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett. 341, 240-247 (2013).
31. Harris, M. L. et al. A dual role for SOX10 in the maintenance of the postnatal melanocyte lineage and the differentiation of melanocyte stem cell progenitors. PLoS Genet. 9, e1003644 (2013).
32. Busam, K. J. et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am. J. Surg. Pathol. 22, 976-982 (1998).
33. Gown, A. M., Vogel, A. M., Hoak, D., Gough, F. & McNutt, M. A. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am. J. Pathol. 123, 195-203 (1986).
34. Ackermann, J. et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005-4011 (2005).
35. Nishimura, E. K. et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416, 854-860 (2002).
36. Chung, Y. R., Schatoff, E. & Abdel-Wahab, O. Epigenetic alterations in hematopoietic malignancies. Int. J. Hematol. 96, 413-427 (2012).
37. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
38. McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989-2994 (2012).
39. Bosenberg, M. et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44, 262-267 (2006).
40. Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21, 70-71 (1999).
41. Rabbani, P. et al. Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell 145, 941-955 (2011).
42. Cotsarelis, G., Sun, T. T. & Lavker, R. M. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61, 1329-1337 (1990).
43. Zipser, M. C. et al. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res. 24, 326-333 (2011).
44. Gaggioli, C. & Sahai, E. Melanoma invasion-current knowledge and future directions. Pigment Cell Res. 20, 161-172 (2007).
45. Saez-Ayala, M. et al. Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell 24, 105-119 (2013).
46. Caramel, J. et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24, 466-480 (2013).
47. Su, I.-H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124-131 (2003).
48. Caganova, M. et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest. 123, 5009-5022 (2013).
49. Tanaka, S. et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107-1117 (2012).
50. Min, J. et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 16, 286-294 (2010).
51. Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768-783 (2013).
52. Shakhova, O. & Sommer, L. Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett. 338, 74-81 (2013).
53. Damsky, W. E. et al. b-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741-754 (2011).
54. Stegmann, A. P. et al. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann. Hematol. 71, 41-47 (1995).
55. Park, M. H., Nishimura, K., Zanelli, C. F. & Valentini, S. R. Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38, 491-500 (2010).
56. Scuoppo, C. et al. A tumour suppressor network relying on the polyaminehypusine axis. Nature 487, 244-248 (2012).
57. Efimenko, E. et al. Caenorhabditis elegans DYF-2, an orthologue of human WDR19, is a component of the intraflagellar transport machinery in sensory cilia. Mol. Biol. Cell 17, 4801-4811 (2006).
58. Lin, B. et al. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin. Cancer Res. 14, 1397-1406 (2008).
59. Shaul, Y. D. et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell 158, 1094-1109 (2014).
60. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480-488 (2013).
61. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
62. Laird, P. W. et al. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 19, 4293 (1991).
63. Bennett, D. C., Cooper, P. J. & Hart, I. R. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 39, 414-418 (1987).
64. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
65. Santoro, R. Analysis of chromatin composition of repetitive sequences: the ChIP-Chop assay. Methods Mol. Biol. 1094, 319-328 (2014).
66. Li, L.-C. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427-1431 (2002).
67. Smyth, G. K. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistics for Biology and Health Vol. 5, 397-420 (Springer, 2005).
68. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
69. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).